Tumor Sequencing to Expand Use of an Immune Checkpoint Inhibitor
The FDA approved the use of a companion diagnostic to identify patients with tumors that have large numbers of genetic mutations.
Progress Against Cancer
The FDA approved the use of a companion diagnostic to identify patients with tumors that have large numbers of genetic mutations.
Identifying people at the highest risk for pancreatic cancer could better identify those who should be screened to catch the disease sooner.
The FDA approved an analog of a marine compound to treat certain patients with small cell lung cancer.
Community level programs were effective and can be expanded to help reduce colorectal cancer disparities, according to a study by National Cancer Institute researchers.
A recent study found that the cost of cancer care in the United States, which was estimated at $183 billion in 2015, is projected to exceed $245 billion by 2030, an increase of more than 30 percent.
The American Cancer Society issues guidelines for diet and physical activity, and more cancer news of the week from Cancer Today.
Immune checkpoint inhibitors kill cancer cells by releasing the brakes on the immune system, thereby allowing it to mount an antitumor response. This form of immunotherapy has led to dramatic responses in some patients; however, most patients’ tumors do not respond to immune checkpoint inhibition, and resistance can develop in tumors that initially respond.
The FDA approved the use of an immune checkpoint inhibitor to treat certain patients with a common form of esophageal cancer.
The vast majority of participants enrolled in nearly 60 prostate cancer clinical trials were non-Hispanic white men, Harvard researchers report.
A recent study reports that high adherence to oral diabetes medication was associated with improved survival for patients with colorectal cancer.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More